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1. Introduction
Immune cells get educated in the thymus during development to recognize self antigens so
that there are no immune responses against self antigens. However, whenever they encounter
non-self antigens like bacteria or viruses, they are recognized as non-self and immune response
takes place against them to save us from infections. While the basic purpose of the immune
response is to save us from infections, something goes awry in some cases such that the self
antigens are recognized as foreign by one’s own immune cells which attack the cells /organs
containing those antigens presuming them to be foreign. This results in auto-immune disor‐
ders like Type 1 diabetes, vitiligo or hypoparathyroidism, the focus for the present chapter.
All these disorders are complex, multi-factorial, organ specific disorders where auto-immune
responses have been implicated due to presence of auto-antibodies and auto-antigen specific
T cells in the peripheral circulation of the patients. Although what triggers the autoimmune
responses in these disorders is not clearly understood, association with certain major histo‐
compatibility complex (MHC) alleles has been considered a hallmark of autoimmune disorders
[1] since they have a role in antigen presentation that orchestrates the antigen specific adaptive
immune responses.
Major Histocompatibility Complex (MHC) is a set of glycoprotein molecules present on the
cell surface of nucleated cells encoded by several polymorphic genes localized on chromosome
6 of man. In human, MHC is known as Human leukocyte Antigens (HLA). MHC region is
spread over 3.84 megabases of chromosome 6p21.3 and is the most gene dense region of the
human genome with 224 genes. 128 of these 224 genes are known to be expressed. And 40 %
of these genes have immune related functions [2]. HLA constitutes a small part of the MHC
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region. Major function of HLA molecules is to present antigenic peptides to T cells. HLA can
be broadly classified into two major classes: class-I and class-II. HLA class-I genes are HLA-
A, -B and –C. These are classical class-I genes which are very polymorphic with 2365, 3005 and
1848 alleles respectively.
The MHC class-I molecules are present on the surface of all nucleated cells and present
antigenic peptides to the CD8+ cytotoxic T cells. MHC class-I molecule is a hetero-dimer of a
heavy and a light chain. The molecular weight of the heavy alpha chain is about 40-45 KDa
and that of the light chain, beta 2 microglobulin (β2m) is 12 KDa [3]. The genes for the alpha
chains are encoded on chromosome 6. However, the gene for β2m is encoded on human
chromosome 15. The heavy chain of the MHC class-I molecule has three domains alpha 1 (α1),
alpha 2 (α2) and alpha 3 (α3). Alpha 1 (α1) and alpha 2 (α2) domains are the most polymorphic
domains since they constitute the peptide binding groove of the MHC molecule. These
polymorphic domains are encoded by exons 2 and 3 of the genes encoding MHC class-I alpha
chain which has in total 8 exons. The peptides that are presented by the MHC molecules have
allele specific motifs i.e., certain peptides can be presented by certain MHC molecules. The
affinity of the peptide to bind to the peptide binding groove is determined by the anchors
present on the peptide binding groove where the peptides go and bind through hydrogen
bonds. Specific motifs or the amino acid residues present in the pockets of the peptide binding
grove which are involved in binding the side chains of complimentary residues of the peptide
determine which peptides would bind to which MHC molecule [4, 5]. Pockets B (key residues
at positions 9, 45, 63, 67, 70 and 99) and F (key residues at positions 77, 80, 81 and 116) of alpha
chain are the main anchors which engage the peptides at their amino acid positions 2 and the
C-terminus [6]. However, several alleles of the MHC share peptide binding specificities i.e.
similar peptides may be presented by different MHC molecules. These alleles are clustered in
supertypes [6].
HLA class-II molecules are expressed on antigen presenting cells like macrophages, dendritic
cells, B cells, thymic epithelium and activated T cells [7]. MHC class-II molecules present
antigenic peptides to the CD4+ T helper cells (Th cells) which in turn initiate a cascade of
immunological events that result in activation of CD8+ cytotoxic T cells and B lymphocytes [2].
CD4+ T helper cells get activated when a non-self antigen is presented to them. T helper cells
are of two types T helper 1 (Th1) and Th2. Th1 cells secrete cytokines like Interferon gamma
and TNF-alpha which are involved in cell-mediated immune responses as they activate the
cytotoxic T cells which have already seen the antigen in the context of MHC class-I. Th2 cells,
on the other hand, secrete IL-4, IL-5 and/or IL-6 which are involved in humoral immunity as
they activate the B cells to become plasma cells which make the antibodies against antigen they
have seen. Thus an immune response takes place which varies in strength depending on the
host factors and the peptides being presented.
The classical MHC class-II glycoproteins in humans are HLA-DR, -DP and –DQ. The MHC
class-II molecule is a heterodimer of two polypeptide chains: an alpha (25-33 KDa) and a beta
chain (24-29KDa) [8, 9]. Unlike MHC class-I, both alpha and beta chains of the class-II molecule
are encoded on chromosome 6. DRB1 gene encodes DR beta chain while DRA1 encodes DR
alpha chain with 1355 DRB1 alleles and 7 DRA1 alleles. Similarly DQB1 and DPB1 encode beta
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chains of DQ and DP molecules with 416 and 190 alleles respectively and DQA1 and DPA1
encode the alpha chains of DQ and DP molecules with 51 and 37 alleles respectively [10, 11].
Besides the classical class-I and class-II genes there are several non-classical HLA genes with
specialized functions and also pseudo HLA genes present in the MHC region. However, they
will not be discussed here since their roles are not very clearly understood in autoimmunity.
A recurring theme of several autoimmune disorders is the aberrant presentation of self
antigens to the immune system that triggers downstream perturbations. Under normal
circumstances most of the MHC molecules are occupied by self peptides and the T cells are
tolerized against them during thymic education so that auto-immune responses do not take
place, however, sometimes there is a break in the tolerance resulting in recognition of self as
non-self by the immune system which results in an auto-immune response. This break in
tolerance could be due to low expression of some antigens in the thymus which may result in
self-reactive T cells to reach the peripheral circulation. Or it could be due to escape of self-
reactive T cells from clonal deletion during T cell development. Since associations with MHC
alleles have been considered a hallmark of autoimmune disorders due to their role in antigen
presentation, we have studied HLA alleles in two common and one rare autoimmune disor‐
ders: Type1 diabetes, vitiligo and hypoparathyroidism.
2. Patients and controls
DNAs were extracted using standard protocol from 10 ml of blood from type 1 diabetes
(N=211), vitiligo (N=1404), hypoparathyroidism patients (N=134) and 902 normal healthy
controls from the same ethnic background after obtaining informed consent. All the patients
attending diabetes of young clinic were carefully assessed and categorized as type 1, type 2
and fibrocalculous pancreatopathy as per the recent classification by American Diabetes
Association expert committee [12, 13]. All of the T1D subjects included in the study required
insulin for glycemic control and 51 of them had history of ketosis at presentation. Insulin
requiring patients with fibrocalculous pancreatopathy and subjects with diabetes in whom
glycemic control was achieved with diet and oral hypoglycemic agent were excluded from the
study [12, 14].
Vitiligo group consisted of 1404 North Indian patients enrolled at Dr. Ram Manohar Lohia
Hospital (RMLH), and All India Institute of Medical Sciences (AIIMS), New Delhi Diagnosis
of vitiligo was based on clinical examination done by dermatologists. Clinically, the cases were
classified as having Generalized (Vulgaris, Acrofacial, Universalis) or Localized (Focal, Acral,
mucosal and segmental) forms of vitiligo. The replication study was done on 355 vitiligo cases
from Gujarat, a state in west of India [15].
Idiopathic hypoparathyroidism group consisted of 134 unrelated patients who attended the
endocrine clinics of All India Institute of Medical Sciences during 1998-2011. The diagnosis of
IH was based on presence of hypocalcemia, hyperphosphatemia, low serum intact PTH,
normal renal function and serum magnesium levels. Patients with post surgical hypopara‐
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thyroidism were not included. Patients with clinical features of APECED syndrome indicated
by mucocutaneous candidiasis or presence of adrenocortical autoantibody were excluded from
the study[16].
Nine hundred and two ethnically matched unaffected controls from North India were used
for all three studies and 441 ethnically matched unaffected controls from Gujarat were studied
in the replication study for vitiligo only. None of the unaffected controls had personal or family
history of T1D, vitiligo, hypoparathyroidism or any other autoimmune or infectious disease.
All Cases and control samples were collected after obtaining informed consent and Institu‐
tional Human Ethics Committee’s clearance from all the institutes/Hospitals involved,
following declaration of Helsinki protocols.
3. Study of HLA-A, HLA-B and HLA–DRB1 alleles
DNA extraction was carried out by standard procedures from fresh whole blood samples
collected in anticoagulant EDTA. Alleles of HLA-A, HLA-B and HLA-DRB1 were studied using
Polymerase chain reaction followed by hybridization with sequence specific oligonucleotide
probes (SSOPs) as described earlier [17] using a bead-based technology (Luminex, Austin, Tx)
following Manufacturer’s instructions (Labtype SSO kit from One Lambda, Canoga Park,
USA). The latest nomenclature for the HLA system was used to designate the alleles of the
three loci studied [18].
4. Statistical analysis
Frequencies of alleles in the patient samples were compared with their respective unaffected
controls using Chi-square analysis and the strength of associations was estimated by odds ratio
(OR) and 95% confidence interval using Stata 9.2 statistical program. Fisher’s exact test was
used when the numbers were five or less in any group i.e. in cases or controls for any allele.
In such cases, Odds ratios were calculated using Woolf’s method [19] with Haldane’s [20]
modification as described earlier [21].
5. Type 1 diabetes
Type 1 diabetes (T1D) is an incurable, multi-factorial and complex autoimmune disorder
characterized by the loss of insulin producing beta cells of the pancreas. This results in
abnormal metabolism of glucose that may be detrimental for several other complications like
ketoacidosis, retinopathy, nephropathy and even cardio-vascular diseases and pre-mature
deaths [22]. World-wide disease affects 1 in 300-400 children [23]. The incidence in South India
has been reported to be 10.5/100,000/year [24]. In North India, a higher prevalence in urban
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(26.6/100,000) as compared to rural areas (4.27/100,000) has been reported with a total preva‐
lence of 10.20/100,000. T1D develops as a result of complex interaction of many genetic and
environmental factors leading to autoimmune destruction of the insulin producing Pancreatic
Beta cells. While 20 genomic intervals have been implicated for the manifestation of the disease
[22], role of an intricate network of the products of these genes cannot be ruled out. However,
unraveling different factors involved and how they interact in integrated networks is like
solving a zig-saw puzzle which is the aim of our studies [12, 14, 17]. However, in this chapter
we will be concentrating on MHC associations and their implications only.
When the patients report to the clinician, he is left with no option but to give daily insulin
injections since most of their pancreatic beta cells are already destroyed. So, if we want to stop
autoimmune responses in the people who are predisposed to get T1D, we need to identify the
prediabetics before the onset of the disease and device ways to inhibit autoimmunity in them.
This is possible by using genetic predisposition criteria to get the disease.
We have studied the frequencies of MHC class-I alleles for HLA-B locus and MHC class-II
alleles for HLA-DRB1 and DQB1 loci in patients with Type 1 diabetes and normal healthy
controls using polymerase chain reaction followed by hybridization with sequence specific
oligonucleotide probes (PCR-SSOP). DNAs were isolated from peripheral blood mononuclear
cells (PBMCs) from patients and healthy controls using standard protocol. The second and
third exons of the HLA-B gene and second exons of HLA-DRB1 and DQB1 genes were
amplified using PCR and hybridized with oligonucleotide probes and the hybridization
pattern with different probes was used to identify the alleles present in a sample. The results
showed that HLA-B*08 (p<7.8X10-13, Odds Ratio (OR) = 3.3), HLA-B*50 (p< 4.2 X 10-21, OR=
7.5), HLA-B*58 (p< 3.3 X 10-6, OR= 2.6), HLA- DRB1*03:01 (p<1.7x10-35, OR= 13.2), DRB1*04:01
(p<0.00001, OR= 5.4), and DRB1*04:05 (p<0.00001, OR=16.01), were significantly increased in
the patients (Figure 1a, b) as compared to controls. We had earlier compared the results of the
T1D patients with 91 healthy controls [14], however, now we have compared the results of
T1D samples with 902 healthy controls, with the same results reinforcing our earlier data. These
results were in concordance with earlier studies in North Indians [25-29]. However, we also
observed DRB1*07:01(p<8x10-6, OR= 0.19) to be significantly decreased in the patients as
compared to controls. In our earlier study when we had less number of controls, we observed
DRB1*04:03 (p< 0.02, OR=0.25) and DRB1*04:04 (p< 0.05, OR= 0.2) also to be significantly
reduced in the patients [14], however, when we increased the number of controls to 902, this
finding did not remain significant, although DRB1*04:03 and DRB1*04:04 were reduced in the
patients but not significantly. We did not find any significant reduction of HLA-DR2 which
has been shown to confer strong protection from T1D in most ethnic groups [30, 31] probably
because the DR2 haplotype which has been shown to be protective i.e., DRB1*15:01-
DQB1*06:02, was observed with a low frequency of only 1.06% in North Indians [21]. On the
other hand, we observed a marginally increased frequency of DRB1*15:01 and reduced
frequency of DRB1*15:06 in patients as compared to controls, which did not remain significant
when p was corrected for the number of alleles tested for DRB1 locus. DRB1*04:03 has been
shown to be associated with protection in a Belgian study on T1D [32]. Our results are in
concordance with studies on T1D patients from Sardinia, black population from Zimbabwe,
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Lithuania, Czecks, Lebanese, Brazilians and African Americans where DRB1*03:01,
DRB1*04:01 and DRB1*04:05 have been shown to be associated with the disease [33-40].
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Figure 1. Distribution of HLA-DRB1, HLA-B and DQB1 alleles in Type 1 diabetes and healthy controls. a. HLA-DRB1
alleles significantly increased or decreased in T1D are shown. DRB1*03:01, *04:01 and *04:05 are significantly in‐
creased and DRB1*07:01is significantly reduced in T1D as compared to controls. b. HLA-B*08, B*50:01 and B*58 are
significantly increased in T1D as compared to controls c. DQB1*02:01 is significantly increased and DQB1*03:01 and
DQB1*05:03 are significantly reduced in T1D as compared to controls. d. Homozygous DRB1*03:01 and heterozygous
DRB1*03:01 with *04:01, *04:05 or any other allele (*0301,X) are significantly increased in T1D as compared to con‐
trols. e. HLA-B-DRB1*03 haplotypes in T1D patients and controls. * denotes alleles that show statistically significant
increase or decrease in the frequencies of the depicted alleles.
HLA-DRB1 and DQB1 are in strong linkage disequilibrium. We also studied the alleles of
DQB1  locus.  DQB1*02:01  which  is  linked  to  DRB1*03:01  was  significantly  increased
(p<1x10-8,  OR=5.08) in patients (Figure 1c). However DQB1*03:02  and DQB1*03:07,  alleles
linked with DRB1*04:01,  DRB1*04:03,  DRB1*04:04  and DRB1*04:05  were not significantly
increased in  the patients  because two of  these  alleles  DRB1*04:01  and DRB1*04:05  were
increased in the patients and the other two DR4 alleles DRB1*04:03 and DRB1*04:04 were
reduced in the patients. DQB1*03:01 (p<6x10-4, OR=0.27) and DQB1*05:03 (6x10-4, OR=0.28)
were reduced in the patients [14].
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Figure 1d shows the homozygosity and heterozygosity of DRB1*03:01 and DRB1*04 alleles
significantly increased in T1D. Homozygous DRB1*03:01 (p<4.6X10-39, OR=23.1), heterozygous
DRB1*03:01/*04:05 (p<5.5X10-6, OR =124.2) and DRB1*03:01/*04:01 (p<0.0001, OR =17.6) were
significantly increased in the patients as compared to controls. Heterozygous 03:01/X (i.e. any
other allele) (p<5.9X10-6, OR = 2.8) was also significantly increased in the patients as compared
to controls. Heterozygous DRB1*07:01/X (p < 1.3X10-7, OR = 0.09) were significantly reduced
in the T1D patients as compared to controls suggesting their protective role. Thirty two percent
of the patients studied were homozygous for DRB1*0301 as compared to 2% of the controls
and this difference was highly significant. Homozygosity of DQB1*02:01 was significantly
(p<1x10-5, OR=5.4) increased in the patients. DQB1*03:02 which was not significantly increased
in the patients, showed a significant increase in heterozygous combination with DQB1*0201
(p<3x10-5, OR=34.16) [14]. In fact none of the controls had DQB1*0201/*0302 heterozygous
combination [14]. In a Swedish study, DQA1*0301/DQB1*0302 and heterozygous combinations
of DQA1*0301/DQB1*0302 and DQA1*0201/DQB1*0501 have been shown to confer the highest
susceptibility [41]
Figure 1 e shows the HLA-B-DRB1 haplotypes that were significantly increased in T1D patients.
HLA alleles are very closely linked to each other in such a way that the haplotypes are inherited
en-bloc. Three HLA-DRB1*03 haplotypes, B*08-DRB1*03:01(p<1x10-14, OR=3.7), B*50-
DRB1*03:01(p<8x10-24, OR=11.2) and B*58-DRB1*03:01 (p<1.4x10-12, OR=5.1) and DRB1*03:01
haplotypes with non B*8/ B*50/ B*58 alleles (p<2.8x10-8, OR=3.4) were significantly increased
in the patients as compared to controls. On the other hand non- B*8/ B*50/ B*58-non
DRB1*03:01 haplotypes were significantly reduced (p<1.5x10-44, OR=0.09) in T1D patients as
compared to controls [12].
Thus our studies show a significant increase of HLA class-I and II alleles which may have a
role in auto-antigen presentation to CD8+ and CD4+ T cells respectively.
6. Vitiligo
Vitiligo is a depigmenting disorder of the skin caused by autoimmune destruction of pigment
producing cells called melanocytes. It effects 0.5-1 % of the world population [42], while in
India the incidence varies from 0.25 to 2.5% [43, 44] in most ethnic groups, however, it has been
reported to be 8.8% in populations from western states of Gujarat and Rajasthan [45]. Vitiligo
manifests in several forms which can be broadly classified in two clinical subtypes: generalized
and localized [42]. While precise etiology of vitiligo is not very well understood, several
hypotheses have been proposed which include autoimmune [46], neural [47], auto-cytotoxic
[48] and genetic hypotheses [49]. However, autoimmune hypothesis gets credence due to co-
occurrence of other autoimmune diseases in vitiligo patients in some cases, presence of auto
reactive T cells and circulating auto-antibodies in the patients [46, 50-55]. The role of genetic
factors has been suggested due to the fact that 7% of first-degree relatives of vitiligo develop
the disease. [56, 57].
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Recent  genome  wide  studies  [58,  59]  have  shown that  several  single  nucleotide  polymor‐
phisms  (SNPs)  in  the  MHC  region  were  significantly  associated  with  the  disease.  Using
imputation based on the previous studies done on associations of HLA, the authors showed
that certain HLA-class-I alleles were associated with vitiligo but they could not impute HLA
class-II alleles. [58]. As mentioned before MHC is the most polymorphic system of the human
genome.  With such a  great  diversity  at  each locus,  linkage disequilibrium (LD) of  HLA
alleles with di-allelic SNPs may not be appropriate since several HLA alleles may be in LD
with one or the alternate SNP. Thus the derivation based on these LDs may not be accurate
especially in the populations from where no previous HLA data is available i.e. if there is
no HLA data available it would be impossible to determine the linkage disequilibrium of
HLA alleles with di-allelic SNPs. So, we conducted a very robust study on a sample size
of 1404 vitiligo cases consisting of 1097 generalized and 307 localized vitiligo cases and 902
unaffected controls from North India for the alleles at HLA-A, -B,(class-I) and -DRB1 (Class-
II) loci using molecular methods and also replicated the study on 355 cases (250 general‐
ized and 105 localized) and 441 controls from Gujarat, a state in west of India [15]. We also
reported differences in the amino acid signatures of peptide binding pockets of the HLA
molecules in vitiligo patients as compared to controls [15].
Our study showed a lot of diversity in number and frequencies of HLA alleles in patients and
controls, with 78, 160 and 106 alleles in cases and 68, 111 and 94 alleles in controls for HLA-A,
-B and -DRB1 loci respectively from North India. Similar diversity was observed in the
replication study as well. However, HLA-A*33:01(p<1.21x10-15, OR=2.57 in North Indians and
p<0.008, OR=1.69 in Gujaratis), B*44:03 (p<7.05x10-27, OR=3.53 in North Indians and
p<1.54x10-8, OR=3.13 in Gujaratis) and DRB1*07:01 (p<3.16x10-30, OR=2.8 in North Indians and
p<9.81x10-15, OR=3.19 in Gujaratis) were significantly increased in both initial and replication
study (Figure 2), suggesting these alleles are the markers for Vitiligo in both North India and
Gujarat. These associations were significant irrespective of the age at onset or the gender of
the cases. So, to determine which HLA alleles have primary association, we sequentially
deleted samples having DRB1*07:01, A*33:01and B*44:03 from both the case and control groups
and then analysed the data for remainder alleles. The analysis showed that association of
DRB1*07:01 with vitiligo seemed to be primary because in the absence of DRB1*07:01, the class-
I alleles A*33:01 and B*44:03 did not remain significantly increased. However, in the absence
of A*33:01and B*44:03, DRB1*07:01 still remained significantly increased in both the popula‐
tions studied. The basic predisposing alleles in both localized and generalized vitiligo are same;
however, similarities with the controls in terms of allele frequencies of some alleles and amino
acid signature of the DR beta chain (figure 3) seem to be protective from generalized distri‐
bution of the lesions in localized vitiligo[15].
Removal of DRB1*07:01 from both patients and control groups resulted in removal of all the
samples that had A*33:01 and B*44:03, suggesting that these alleles being on the same chro‐
mosome may be making a haplotype, such that when samples with DRB1*07:01 are removed
they also get removed simultaneously. To prove that we estimated the HLA haplotype
frequencies using the expectation-maximization (EM) algorithm [60, 61] using Arlequin Ver
3.5 (http://cmpg.unibe.ch/software/arlequin35/). Haplotype analysis for three loci showed
HLA and Associated Important Diseases208
haplotypes A*33:01-B*44:03-DRB1*07:01 (p<8.75x10-23, OR=6.21 in North Indians and
p<0.000016, OR=3.65 in Gujaratis) and A*24:02-B*44:03-DRB1*07:01 (p<0.0019, OR=3.83 in
North Indians and p<0.0034, OR=7.73 in Gujaratis) were significantly increased and A*26:01-
B*08:01-DRB1*03:01 was significantly reduced (p<0.00005, OR=0.33 in North Indians and
p<0.0007, OR=0.15 in Gujaratis) in vitiligo patients in both the initial study as well as in the
replication study. Analysis of two-locus haplotypes revealed haplotypes A*33:01-
DRB1*07:01 (p<6.97x10-26, OR=6.55 in North Indians and p<0.00001, OR=3.59 in Gujaratis) and
B*44:03-DRB1*07:01 (p < 2.4 x 10-29, OR=4.01 in North Indians and p<1.84x10-14, OR=6.34 in
Gujaratis) was significantly increased and A*26:01-DRB1*03:01 was significantly reduced
(p<0.00005, OR=0.33 in North Indians and p<0.0007, OR=0.15 in Gujaratis) in vitiligo cases in
both initial and replication study[15].
We further studied the amino acid signatures of the peptide binding pockets of DRB1 in vitiligo
cases and unaffected controls Eleven residues representing integral parts of peptide binding
pockets of DR beta chain were analysed at positions 26, 28, 30, 37, 47, 67, 70, 71, 74, 77 and 86
[62]. The protein sequences were downloaded for all the alleles observed from the HLA
database (http://www.ebi.ac.uk/cgi-bin/imgt/HLA/align.cgi) and the amino acids present at
North Indians 
* * 
*  * * *  * 
* *  * 
 * 
*  
Gujaratis (replication study) 
 *   *   * 
 *  * 
*  *  * 
* * * 
 *  * * 
 *   *   * 
* * 
* * * 
 *  * 
Singh et al.,  Journal of Investigative Dermatology,2012 
* * 










* * * 
Figure 2. HLA-A, B and DRB1 loci alleles significantly increased in all vitiligo, generalized vitiligo and localized vitiligo
patients when compared with healthy controls in North Indian and Gujarat patients. * denotes alleles that show statis‐
tically significant increase or decrease in the frequencies of the depicted alleles.
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the aforesaid positions were compared in patients with controls. Figure 3 shows the amino
acid residues at the aforesaid positions that were either significantly increased or decreased in
all vitiligo patients, generalized and localzed vitiligo patients when compared with controls.
The results show that Glu28β, Leu30β/Arg30β Phe37β, Tyr47β, Ile67β, Asp70β, Arg71β, Gln74β, Thr77β and
Gly86β make the molecular signature of the peptide binding pockets of DRB1 for predisposition
to develop vitiligo in both the initial as well as in the replication study (Figure 3). Asp28β, Tyr30β/
Cys30β, Ser37β, Phe47β, Leu67β, Gln70β, Lys71β, Ala/Arg74β, Asn77β and Val86β make the molecular
signature for the protection from Vitiligo in both North India and Gujarat. [15].
We observed subtle differences in the molecular signatures of the peptide binding pockets of
DR beta chain in localized and generalized vitiligo. Localized vitiligo patients show similarities
in the amino acid signatures with not only generalized vitiligo but also with healthy controls
probably responsible for localized distribution of the lesions in them. Amino acid signature at
positions Glu28β, Leu30β, Phe37β, Tyr47β and Gln74β in the localized vitiligo patients is similar to
  
 Position 28 30 30 37 47 67 70 71 74 77 86 
Amino Acid E L R F Y I D R Q T G 
North Indians All Vitiligo                       
Gujaratis All Vitiligo                       
North Indian Generalized                        
Gujaratid Generalized                        
North Indian Localized                        
Gujarati Localized                        
Position 28 30 30 37 47 67 70 71 74 74 77 86 
Amino Acid D Y C S F L Q K A R N V 
North Indians All Vitiligo                         
Gujaratis All Vitiligo                         
North Indian Generalized                          
Gujaratid Generalized                          
North Indian Localized                          
Gujarati Localized                          
  Significantly increased <0.009 to 10-6 
  Significantly increased p<0.01 to 0.05 
  Non significant 
  Significantly reduced p<0.01 to 0.05 
  Significantly reduced p<0.009 to 10-6 
Figure 3. Amino acid signatures for the peptide binding pockets of HLA molecules for DR beta1 chain in all vitiligo,
generalized vitiligo and localized vitiligo patients from North India and Gujarat. Amino acids shown in red are signifi‐
cantly increased in vitiligo patients while amino acids shown in green are significantly reduced in vitiligo patients as
compared to controls and those in black are not significantly different from controls (Singh et al., JID, 2012).
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generalized vitiligo in both the initial and replication study. However, the amino acid signature
similar to healthy controls were observed at positions Arg30β/Cys30β, Ser37β, Ile67β/Leu67β Asp70β,
Ala74β in North Indians and Cys30β, Ser37β, Asp70β, Arg71β/Lys Ser71β, Ala74β/ Arg74β and Thr77β /
Asn77β in Gujaratis [15].
Most of the studies previously have been done on Generalized vitiligo which has been
considered to be an autoimmune disease. We showed for the first time that both generalized
and localized vitiligo have the same predisposing MHC alleles i.e., B*44:03 and DRB1*07:01 in
both the populations studied. Association of MHC alleles with localized vitiligo clearly
suggests an autoimmune etiology of the disease due to antigen presenting function of the MHC
molecules. Thus there seems to be a need to re-look at the aetiopathogenesis of localized vitiligo
in light of our results. While it may be an autoimmune disorder, similarities with unaffected
controls in terms of HLA alleles and amino acid signature of the peptide binding pockets of
DR beta chain may be contributing to the localized distribution of the lesions [15].
7. Idiopathic hypoparathyroidism
Idiopathic hypoparathyroidism (IH) is a rare endocrine disease where parathyroid gland is
functionally impaired resulting in subnormal PTH secretion, hypocalcemia, hyperphospha‐
temia and associated complications [63]. While it may be an autoimmune disorder [63], there
is hardly any evidence to confirm the autoimmune etiology of the disease. Since there was no
comprehensive study on the immunogenetic basis of IH, we studied the association of HLA
class-I and II alleles in a large group of North Indian patients (N=134) with IH [16, 64-70] and
compared them to 902 healthy controls from the same ethnic background. We also reported
significant differences in the amino acid signatures of peptide binding pockets of the HLA
molecules in patients with IH as compared with controls [16].
Just like vitiligo, we observed diversity in number and frequencies of HLA alleles with 23, 40
and 44 alleles in patients for HLA-A, -B, and -DRB1 loci, respectively. However, specific alleles
at these loci were found to be predisposing. HLA-A*26:01 (p<1.71x10-34, OR = 9.29), HLA-
B*08:01 (p<8.19x10-6, OR = 2.59), and HLA-DRB1*03:01 (p<0.013, OR = 1.67) and HLA-
DRB1*12:02 (p<0.0046, OR = 3.52) were significantly increased in IH when compared with
healthy controls. However, alleles HLA-A*01:01 (p<0.039, OR = 0.60), HLA-A*03:01 (p<0.004,
OR=0.33), HLA-B*15:01 (p<0.0038, OR=0.17) and HLA-B*57:01 (p<0.0074, OR=0.3) were signif‐
icantly reduced in IH as compared with controls (Figure 4a). Since HLA-A*26:01 showed the
highest significance, we studied whether any other allele was significantly increased in the
absence of HLA-A*26:01. So, all the samples with A*26:01 were removed from both cases and
controls and then analysis was done for significant differences in frequencies of the remainder
alleles. In the absence of HLA-A*26:01, no other allele showed any significant differences [16].
Associations of A*26:01 and B*08:01 with IH were significant irrespective of the gender and
age at onset of the disease. To investigate whether there was any association of HLA alleles
with associated clinical autoimmunity in IH, patients were categorized into two groups, those
with associated clinical autoimmunity and those without. While HLA-A*26:01 was signifi‐
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cantly increased in both the groups as compared with controls, HLA-B*08:01 and DRB1*12:02
were significantly increased in patients without any associated clinical autoimmunity when






















Figure 4. HLA-A, B and DRB1 loci alleles significantly increased in idiopathic hypoparathyroidism patients when com‐
pared with healthy controls in North Indian patients. * denotes alleles that show statistically significant increase or
decrease in the frequencies of the depicted alleles.
We constructed HLA haplotypes for HLA-A-B-DRB1 and HLA-A-B and HLA-A-DRB1 for 133
cases and 902 controls using Arlequin 3.5 program (http://cmpg.unibe.ch/software/arle‐
quin35/). Haplotype HLA-A*26:01-B*08:01-DRB1*03:01 (p<4.47x10-8, OR = 4.38), was signifi‐
cantly increased in cases as compared with controls. Two locus haplotype analysis (figure
4b) showed haplotypes A*26:01-B*08:01(p<1.48x10-11, OR = 4.72), A*26:01-B*51:01 (p<7.59x10-6,
OR = 17.26), A*26:01-B*35:03 (p<0.0028, OR = 8.48), and A*11:01-B*40:06 (p<0.0009, OR = 4.46),
were significantly increased in IH as compared to controls. However, the association of A*26:01
with IH seems to be primary since in the absence of A*26:01, none of the other alleles like
B*08:01, B*51:01 or DRB1*03:01 remained significantly different suggesting that the significant
increase in these alleles is due to their being in linkage disequilibrium with the A*26:01[16].
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MHC molecules are extremely polymorphic, however, alleles with similar peptide binding
pockets may be clustered in one group [6], called supertypes, such that HLA molecules in one
supertype may present similar peptides[16]. Assignment of alleles in the supertypes have been
done based on published motifs, binding data, shared repertoires of binding peptides and the
amino acid sequences of different alleles at the peptide binding pockets [6]. Supertype A01
(which includes A*26:01) was significantly increased in IH with 65.67% of the patients as
compared to 39.36% of the controls having this supertype (figure 4 c). However, A*26:01 was
observed only in 50.75% of the patients as compared to 9.98% of the controls. About 15% of
the IH cases had different alleles of A01 supertype (other than A*26:01), which did not show
statistically significant differences due to small numbers. Significant increase of A01 supertype
suggests that similar auto-antigenic peptides may be getting presented by different MHC
molecules which belong to the supertype [6, 16].
While the amino acid residue at a particular position in different alleles in a supertype may
not be the same, they would be similar in nature such that they would bind similar peptides.
For instance, all the alleles falling in supertype A01 will bind small and aliphatic residues in
the B pocket and aromatic and large hydrophobic residues in F pocket [6]. Thus, the nature of
the shared amino acids and not amino acid per se constitutes the molecular signatures of the
peptide binding groove of different alleles in a supertype.
The peptide binding groove of the MHC class-I molecules contain small pockets where the
side chains of complimentary residues of the peptide bind [4]. Pockets B (key residues at
positions 9, 45, 63, 67, 70 and 99) and F (key residues at positions 77, 80, 81 and 116) of alpha
chain are the main anchors which engage the peptides at its amino acid position 2 and the C-
terminus [6]. Since we observed a significant increase in an HLA-A locus allele (HLA-
A*26:01), we analysed the amino acid signatures of the peptide binding groove of the alleles
of A-locus to check for shared peptide binding specificity. For this purpose, the protein
sequences of the HLA-A locus alleles were downloaded from the HLA database as mentioned
for the vitiligo study and the amino acids present at the aforesaid positions were compared in
patients with controls. We observed that Tyr9α, Asn63α, Val67α, His70α, Asn77α, Ile80α and Ala81α
make the molecular signature for HLA-A peptide binding pockets for predisposition to IH,
however, Phe9α, Glu63α, Met67α, Gln70α, Asp77α, Thr80α and Leu81α make the molecular signature
for negative association with the disease (Figure 4d). While the most significant association
was derived from HLA-A*26:01, peptide binding grooves of other alleles shared some of the
residues with the peptide binding grove of HLA-A*26:01 (Figure 5)[16].
MHC is the most polymorphic system of the man with more than 6000 alleles for different loci.
With such a great diversity, association of particular MHC alleles with a disease has functional
implications due to the antigen presenting function of the MHC. The peptides presented by
the MHC molecules have allele specific motifs [4]. The affinity of the peptide to a particular
MHC molecule is determined by the amino acid residues present in peptide binding pockets
of the peptide binding groove. Shared amino acids in the peptide binding pockets have been
demonstrated in autoimmune diseases like Type 1 diabetes [71], rheumatoid arthritis [72] and
thyroiditis [62]. Investigation of amino acid signatures for the peptide binding pockets of HLA-
A and HLA-B alpha chain and HLA-DR beta chain revealed specific molecular signatures for
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predisposition and protection from these diseases. Our data shows that haplotypes B*8-
DRB1*03:01, B*50-DRB1*03:01 and B*58-DRB1*03:01 were significantly increased in T1D
patients [12]. A*26:01-B*08:01-DRB1*03:01 and A*26:01 with other B-locus alleles were signif‐
icantly increased in hypoparathyroidism [16]. And in yet another autoimmune disorder,
vitiligo, A*33:01-B*44:03-DRB1*07:01 is the predisposing haplotype and A*26:01-B*08:01-
DRB1*03:01 seems to be protective haplotype, with DRB1*07:01 having primary association
with the disease [15]. While in T1D and vitiligo it is the MHC class-II allelesDRB1*03:01
andDRB1*07:01 respectively, which had primary association, in hypoparathyroidism it is the
MHC class-I allele HLA-A*26:01 which has primary association. Interestingly, in T1D
DRB1*03:01 is predisposing and DRB1*07:01 is protective from the disease. However, in
vitiligo it is exactly the opposite i.e., DRB1*07:01 is predisposing and DRB1*03:01 is protective.
 
HLA-A  N=259 Position Position Position Position Position Position Position supertypes 
 *Alleles No. 9 63 67 70 77 80 81   
A*26:01 68 Y N V H N I A A01 
A*0101 22 F E M H N T L A01 
A*29:01 5 T Q V Q N T L A01 
A*30:01 4 S E V Q D T L A01 
A*32:01 3 F E V H S I A A01 
A*26:25N 1 Y N V P N T L A01 
A*11:01 42 Y E V Q D T L A03 
A*68:01 18 Y N V Q D T L A03 
A*24:02 28 S E V H N I A A24 
A*23:01 1 S E V H N I A A24 
A*23:15 1 S E V H N I A A24 
A*24:07 1 S E V Q N I A A24 
A*02:06 4 Y E V H D T L A02 
A*02:05 3 Y E V H D T L A02 
A*33:01 10 T N V H D T L A03 
A*33:03 2 T N V H D T L A03 
A*30:36 1 S E V Q D T L A03  
A*02:01 13 F E V H D T L A02 
A*02:11 12 F E V H D T L A02 
A*02:03 6 F E V H D T L A02 
A*03:01 7 F E V Q D T L A03 
A*31:01 6 T E V H D T L A03 
A*03:02 1 F E V Q D T L A03 
 
Figure 5. Amino acid signatures (single letter codes) of the peptide binding pockets and HLA supertypes of 23 HLA-
  p < 0.017 to 1.06x10-10, Significantly increased in IH as compared to controls 
  p < 0.017 to 4.79x10-10, Significantly reduced in IH as compared to controls 
Figure 5. Amino acid signatures (single letter codes) of the peptide binding pockets and HLA supertypes of 23 HLA-A
locus alleles observed in IH cases showing significant increase or decrease in the number of amino acids. N=259 indi‐
cates 259 alleles were observed in 134 patients which were compared with amino acid signatures of 1698 alleles from
902 controls.
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These data suggest the autoantigenic peptides presented by different MHC molecules are
restricted by these common alleles in a population which are associated with the autoimmune
disorders. Of about 350 alleles that were observed in the three patient groups and healthy
controls, A*26:01 (9.98%), A*33:01 (11.53%), B*08:01 (12.42%), B*44:03 (10.75%), DRB1*03:01
(19.29%) and DRB1*07:01 (27.49%), were quite common alleles in the healthy North Indians
that were associated with the three autoimmune disorders discussed above.
Our results suggest affinity of auto-antigenic peptides for predisposing MHC class-II and class-
I molecules which may be involved in orchestrating (through CD4+ T cells) and implementing
the autoimmune responses (through CD8+ T cells) in Type 1 diabetes, vitiligo and hypopara‐
thyroidism.
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